Home | Business News | Browse by Publication | M | M2 Presswire

OTCPicks.com Daily Market Movers Digest Midday Report for Friday, May 30th CABN, GNTA, KIRK, SLTN, WTSLA.

Article Excerpt
M2 PRESSWIRE-30 May 2008-OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Friday, May 30th CABN, GNTA, KIRK, SLTN, WTSLA(C)1994-2008 M2 COMMUNICATIONS LTD

RDATE:30052008

Our Stocks to Watch today include Carbon Sciences Inc. (OTCBB: CABN), Genta Inc. (OTCBB: GNTA), Kirkland's Inc. (NASD: KIRK), Solar Thin Films Inc. (OTCBB: SLTN), The Wet Seal Inc. (NASD: WTSLA)

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

CARBON SCIENCES INCORPORATED (OTCBB: CABN)

Detailed Quote: http://www.otcpicks.com/quotes/CABN.php

Company Profile: http://www.otcpicks.com/carbon-sciences/carbon-sciences-2.htm

Carbon Sciences, Inc. focuses on developing GreenCarbon technology to convert carbon dioxide into a form that would not contribute to global warming. Its GreenCarbon technology is targeted at coal-fired electrical power plants and fuel production plants. The company was founded in 2006 as Zingerang, Inc. and changed its name to Carbon Sciences, Inc. in April 2007. Carbon Sciences, Inc. is based in Santa Barbara, California.

CABN News:

May 28 - Carbon Sciences Files International Patent

Company Seeks Worldwide Protection for Its Innovative CO2 Transformation Technology

Carbon Sciences, Inc. (OTCBB: CABN), the developer of a breakthrough technology to transform harmful carbon dioxide (CO2) into high value, earth-friendly products, has recently deposited an international PCT patent application pursuant to last year's filing of United States patent application 11/749,741 with the US Patent Office. The international application is related to the Company's innovative method for carbon dioxide transformation and sequestration.

As indicated by Wesley B. Ames, patent agent from the firm Ames IP Law, "This PCT application has been filed so as to protect the various highly innovative technologies being developed by Carbon Sciences, Inc. concerning carbon dioxide transformation."

This international PCT application should be published by the end of November 2008. The Company looks forward to proceeding with the national phase entries in various countries by November 2009 in order to protect its technologies in countries with important mining industries.

"We are particularly proud of the fact that the technologies we are developing will have international impact," indicated Derek McLeish, Carbon Sciences CEO. "As we continue to develop our intellectual property portfolio, we are also exploring relationships with potential strategic partners to enable worldwide transformation of carbon dioxide."

GENTA INCORPORATED (OTCBB: GNTA) "Up 22.58% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GNTA.php

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, visit www.genta.com.

GNTA News:

May 30 - Genasense Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy

Genta Incorporated (OTCBB: GNTA) announced preliminary results that have shown a high objective response rate in a pilot study that incorporates the Company's lead oncology product, Genasense (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced melanoma. In this study, Genasense was used to potentially enhance the clinical activity of temozolomide (Temodar ; Schering Plough, Inc.), the most commonly used anticancer drug for melanoma, combined with Abraxane (paclitaxel protein-bound particles for injectable suspension; Abraxis Bioscience, Inc.). The data will be featured in a presentation at the annual meeting of the American...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!